<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03531905</url>
  </required_header>
  <id_info>
    <org_study_id>1002FDC-058</org_study_id>
    <nct_id>NCT03531905</nct_id>
  </id_info>
  <brief_title>Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C</brief_title>
  <official_title>A Randomized Study to Evaluate the Efficacy and Safety of Bempedoic Acid 180 + Ezetimibe 10 Fixed-Dose Combination Compared to Ezetimibe and Placebo In Subjects With T2DM and Elevated LDL-Cholesterol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Esperion Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Esperion Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      12 week study to assess the LDL-C lowering efficacy, other lipid and glycemic measures, and
      safety of bempedoic acid/ezetimibe FDC compared to ezetimibe and placebo in patients with
      type 2 diabetes (T2D) and elevated LDL-C
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assess efficacy of FDC vs. ezetimibe vs. placebo for 12 week LDL-C lowering, changes in
      atherogenic lipids, hsCRP and exploratory glycemic measures as well as safety in patients
      with type 2 diabetes and elevated LDL-C.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2018</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LDL-C lowering FDC vs. Placebo</measure>
    <time_frame>12 week</time_frame>
    <description>Percent change from baseline to week 12 for LDL-C; FDC vs. Placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LDL-C lowering FDC vs. Ezetimibe</measure>
    <time_frame>12 week</time_frame>
    <description>Percent change from baseline to week 12 for LDL-C; FDC vs. Ezetimibe</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LDL-C lowering Ezetimibe vs. Placebo</measure>
    <time_frame>12 week</time_frame>
    <description>Percent change from baseline to week 12 for LDL-C; Ezetimibe vs. Placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hs-CRP FDC vs. Ezetimibe</measure>
    <time_frame>12 week</time_frame>
    <description>Percent change from baseline to week 12 for hs-CRP; FDC vs. Ezetimibe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hs-CRP FDC vs. Placebo</measure>
    <time_frame>12 week</time_frame>
    <description>Percent change from baseline to week 12 for hs-CRP; FDC vs. Placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hs-CRP Ezetimibe vs. Placebo</measure>
    <time_frame>12 week</time_frame>
    <description>Percent change from baseline to week 12 for hs-CRP; Ezetimibe vs. Placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in non-HDL-C; FDC vs. Ezetimibe</measure>
    <time_frame>12 week</time_frame>
    <description>Percent change from baseline to week 12 for non-HDL-C; FDC vs. Ezetimibe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in non-HDL-C; FDC vs. Placebo</measure>
    <time_frame>12 week</time_frame>
    <description>Percent change from baseline to week 12 for non-HDL-C; FDC vs. Placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in non-HDL-C; Ezetimibe vs. Placebo</measure>
    <time_frame>12 week</time_frame>
    <description>Percent change from baseline to week 12 for non-HDL-C; Ezetimibe vs. Placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in apoB; FDC vs. Ezetimibe</measure>
    <time_frame>12 week</time_frame>
    <description>Percent change from baseline to week 12 for apoB; FDC vs. Ezetimibe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in apoB; FDC vs. Placebo</measure>
    <time_frame>12 week</time_frame>
    <description>Percent change from baseline to week 12 for apoB; FDC vs. Placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in apoB; Ezetimibe vs. Placebo</measure>
    <time_frame>12 week</time_frame>
    <description>Percent change from baseline to week 12 for apoB; Ezetimibe vs. Placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total cholesterol; FDC vs. Ezetimibe</measure>
    <time_frame>12 week</time_frame>
    <description>Percent change from baseline to week 12 for total cholesterol; FDC vs. Ezetimibe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total cholesterol; FDC vs. Placebo</measure>
    <time_frame>12 week</time_frame>
    <description>Percent change from baseline to week 12 for total cholesterol; FDC vs. Placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total cholesterol; Ezetimibe vs. Placebo</measure>
    <time_frame>12 week</time_frame>
    <description>Percent change from baseline to week 12 for total cholesterol; Ezetimibe vs. Placebo</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in hemoglobin A1c; FDC vs. Ezetimibe</measure>
    <time_frame>12 week</time_frame>
    <description>Percent change from baseline to week 12 for hemoglobin A1c; FDC vs. Ezetimibe</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in hemoglobin A1c; FDC vs. Placebo</measure>
    <time_frame>12 week</time_frame>
    <description>Percent change from baseline to week 12 for hemoglobin A1c; FDC vs. Placebo</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in hemoglobin A1c; Ezetimibe vs. Placebo</measure>
    <time_frame>12 week</time_frame>
    <description>Percent change from baseline to week 12 for hemoglobin A1c; Ezetimibe vs. Placebo</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in fasting glucose; FDC vs. Ezetimibe</measure>
    <time_frame>12 week</time_frame>
    <description>Percent change from baseline to week 12 for fasting glucose; FDC vs. Ezetimibe</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in fasting glucose; FDC vs. Placebo</measure>
    <time_frame>12 week</time_frame>
    <description>Percent change from baseline to week 12 for fasting glucose; FDC vs. Placebo</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in fasting glucose; Ezetimibe vs. Placebo</measure>
    <time_frame>12 week</time_frame>
    <description>Percent change from baseline to week 12 for fasting glucose; Ezetimibe vs. Placebo</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in 2-hour postprandial glucose; FDC vs. Ezetimibe</measure>
    <time_frame>12 week</time_frame>
    <description>Percent change from baseline to week 12 for 2-hour postprandial glucose; FDC vs. Ezetimibe</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in 2-hour postprandial glucose; FDC vs. Placebo</measure>
    <time_frame>12 week</time_frame>
    <description>Percent change from baseline to week 12 for 2-hour postprandial glucose; FDC vs. Placebo</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in 2-hour postprandial glucose; Ezetimibe vs. Placebo</measure>
    <time_frame>12 week</time_frame>
    <description>Percent change from baseline to week 12 for 2-hour postprandial glucose; Ezetimibe vs. Placebo</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in HOMA-IR; FDC vs. Ezetimibe</measure>
    <time_frame>12 week</time_frame>
    <description>Percent change from baseline to week 12 for HOMA-IR; FDC vs. Ezetimibe</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in HOMA-IR; FDC vs. Placebo</measure>
    <time_frame>12 week</time_frame>
    <description>Percent change from baseline to week 12 for HOMA-IR; FDC vs. Placebo</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in HOMA-IR; Ezetimibe vs. Placebo</measure>
    <time_frame>12 week</time_frame>
    <description>Percent change from baseline to week 12 for HOMA-IR; Ezetimibe vs. Placebo</description>
  </other_outcome>
  <other_outcome>
    <measure>Treatment-emergent adverse events</measure>
    <time_frame>12 week</time_frame>
    <description>Safety and tolerability as measured by rates of treatment-emergent adverse events in each arm</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Cholesterolemia</condition>
  <arm_group>
    <arm_group_label>Bempedoic acid + Ezetimibe FDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bempedoic acid + Ezetimibe FDC Oral Tablet; Placebo oral capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ezetimibe 10 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ezetimibe 10Mg Oral Tablet; Placebo Oral Tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Oral Tablet, Placebo oral capsul</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bempedoic acid + Ezetimibe FDC Oral Tablet</intervention_name>
    <description>Experimental therapy of bempedoic acid 180 mg + ezetimibe 10 mg FDC tablet</description>
    <arm_group_label>Bempedoic acid + Ezetimibe FDC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe 10Mg Oral Tablet</intervention_name>
    <description>Ezetimibe 10 mg tablet, overencapsulated for blinding purposes</description>
    <arm_group_label>Ezetimibe 10 mg</arm_group_label>
    <other_name>Zetia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo tablet, matched for the FDC product for blinding purposes</description>
    <arm_group_label>Ezetimibe 10 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Placebo over-encapsulated for blinding purposes</description>
    <arm_group_label>Bempedoic acid + Ezetimibe FDC</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes for 6 months or greater

          -  Currently taking stable diabetes medication for 3 months or greater

          -  HbA1c between 7-10%

          -  LDL-cholesterol greater than 70 mg/dL

          -  Women must not be pregnant, lactating, or planning to become pregnant within 30 days
             after last dose of study medication; and must be postmenopausal, surgically sterile,
             or willing to use 1 acceptable form of birth control during the study through 30 days
             after the last dose of study medication

        Exclusion Criteria:

          -  Body mass index &gt; 40 kg/m2

          -  History of documented clinically significant cardiovascular disease

          -  Fasting triglycerides &gt; 400 mg/dL

          -  History of Type 1 diabetes

          -  Uncontrolled hypothyroidism, liver dysfunction, renal dysfunction, gastrointestinal
             condition that may affect drug absorption, hematologic or coagulation disorder or
             active malignancy

          -  History of drug or alcohol abuse within 2 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JoAnn Flaim, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Esperion Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeffrey C Hanselman, MS</last_name>
    <phone>734-887-3925</phone>
    <email>clinical@esperion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Trials Research</name>
      <address>
        <city>Lincoln</city>
        <state>California</state>
        <zip>95648</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>FInlay Medical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>L-MARC Research Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hampton Roads Center for Clinical Research</name>
      <address>
        <city>Suffolk</city>
        <state>Virginia</state>
        <zip>23435</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gutierrez MJ, Rosenberg NL, Macdougall DE, Hanselman JC, Margulies JR, Strange P, Milad MA, McBride SJ, Newton RS. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2014 Mar;34(3):676-83. doi: 10.1161/ATVBAHA.113.302677. Epub 2014 Jan 2.</citation>
    <PMID>24385236</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2018</study_first_submitted>
  <study_first_submitted_qc>May 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2018</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>cholesterolemia</keyword>
  <keyword>type 2 diabetes</keyword>
  <keyword>LDL-C</keyword>
  <keyword>T2D</keyword>
  <keyword>diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

